͵͵

Journal News

Plasma membrane is no barrier to free fatty acid

Nathalie Gerassimov
Oct. 27, 2020

Our understanding of how long-chain fatty acids cross membranes is changing based on recent work by oratory at Boston University and others. Their research shows that unlike nutrients such as glucose or amino acids, which require a transporter, fatty acids can diffuse spontaneously through protein-free lipid bilayers and cells’ plasma membranes.

A in the Journal of Lipid Research by Anthony Jay and colleagues reveals how molecules previously thought to inhibit fatty acid transport specifically, including sulfosuccinimidyl oleate, or SSO, fit the diffusion model.

Control of fatty acid entry into cells is difficult to visualize. Researchers often have used fatty acid metabolites that become trapped in the cell to infer transport by plasma membrane proteins. The Hamilton lab has focused on distinguishing transmembrane movement from metabolism.

The lab made a that transport of fatty acids across a bilayer can be followed by pH changes. They combined a with phospholipid vesicles enclosing a pH-probe to measure absorption in real time. They showed that natural fatty acids can acquire a proton near the outer leaflet, leading to equilibrium between neutral and ionized forms. The net neutral fatty acid spontaneously diffuses across the bilayer and then releases the proton near the inner leaflet, reducing the internal pH. This energy-free diffusion has been termed the “flip-flop” mechanism.

JLR-schematic-762x423.jpg
James Hamilton/JLR
This schematic shows that (A) sulfosuccinimidyl oleate can flip-flop across the bilayer to enter cells, and (B) it can modify amino acids.

“Our studies also showed that all fatty acids studied … exhibit rapid flip-flop, and that this mechanism is reversible,” Hamilton said.

The researchers were excited by this finding but acknowledge that it does not exclude a role for proteins. Jay said, “If fatty acids can simply diffuse into cells, how could there be inhibitors of this transmembrane movement?”

The recent paper tests several proposed transport inhibitors, including the gold standard, SSO. Scientists had described SSO as a specific inhibitor of fatty acid entry into cells that acts on the fatty acid transporter CD36 without penetrating membranes. However, Hamilton’s team showed that SSO crosses membranes. Immunofluorescence using novel antibodies that bind SSO-linked fatty acids suggested that SSO modifies numerous proteins on the cell surface and interior, refuting the assumption of CD36 specificity.

The research informs nutritional considerations, Hamilton said. “Metabolism, and not the plasma membrane, controls the retention of fatty acids in cells, by trapping the fatty acids. Although membrane proteins may bind fatty acids or participate in metabolism, they cannot block diffusion in the surrounding bilayer.”

JLR-Res-617x460.jpg
James Hamilton/JLR
These image show immunofluorescence staining of amino acids modified with the fatty acid transporter CD36
and the fatty acid transport inhibitor sulfosuccinimidyl oleate. The insert on the right suggest that SSO staining is not
exclusive to CD36.

In fact, but CD36 increased the content of intercellular lipids.

For nutrition, Hamilton emphasized, “Healthy fatty acids such as omega 3 fatty acids need to enter cells readily, whereas unhealthy fatty acids, such as trans fatty acids, cannot be excluded from cells and need to be reduced in the diet.”

Hamilton’s lab is moving on to clinical trials using a high concentration of beneficial fatty acids to improve stroke and heart attack outcomes. Meanwhile, he recommends taking omega-3 supplements and eating more nuts.

Another interpretation

According to Maastricht University researchers Jan Glatz and Joost Luiken, the Hamilton lab’s results also could be interpreted as a step toward integration of the argument that fatty acids diffuse across the cell membrane and the view that the protein CD36 is required for fatty acid uptake. In a , Glatz and Luiken lay out their view that CD36 may be helpful but not necessary for lipid uptake.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Nathalie Gerassimov

Nathalie Gerassimov is a postdoctoral researcher at the Carnegie Institution of Washington department of embryology.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Guiding grocery carts to shape healthy habits
Award

Guiding grocery carts to shape healthy habits

Nov. 21, 2024

Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.

Quantifying how proteins in microbe and host interact
Journal News

Quantifying how proteins in microbe and host interact

Nov. 20, 2024

“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.

Leading the charge for gender equity
Award

Leading the charge for gender equity

Nov. 19, 2024

Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.

CRISPR gene editing: Moving closer to home
News

CRISPR gene editing: Moving closer to home

Nov. 17, 2024

With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.

Finding a missing piece for neurodegenerative disease research
News

Finding a missing piece for neurodegenerative disease research

Nov. 16, 2024

Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.

From the journals: JLR
Journal News

From the journals: JLR

Nov. 15, 2024

Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.